Recent Finacing
Recent Raise
Milestone Pharmaceuticals is a Montreal-based clinical-stage cardiovascular company developing etripamil (MSP-2017), a short-acting intranasal calcium-channel blocker for patient‑administered termination of PSVT, currently in late-stage clinical trials.
